©DANIEL ROUSSELOT/Sanofi

Sanofi and Regeneron Provide Update on Kevzara® (sarilumab) Phase 3 U.S. Trial in COVID-19 Patients

Originally published on sanofi.com.

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints when Kevzara was added to best supportive care compared to best supportive care alone (placebo).

Minor positive trends were observed in the primary pre-specified analysis group (critical patients on Kevzara 400 mg who were mechanically ventilated at baseline) that did not reach statistical significance and these were countered by negative trends in a subgroup of critical patients who were not mechanically ventilated at baseline1. In the primary analysis group, adverse events were experienced by 80% of Kevzara patients and 77% of placebo patients. Serious adverse events that occurred in at least 3% of patients and more frequently among Kevzara patients were multi organ dysfunction syndrome (6% Kevzara, 5% placebo) and hypotension (4% Kevzara, 3% placebo).

Based on the results, the U.S.-based trial has been stopped, including in a second cohort of patients who received a higher dose of Kevzara (800 mg). Detailed results will be submitted to a peer-reviewed publication later this year.

The primary analysis group included 194 patients who were critically ill with COVID-19 and receiving mechanical ventilation at the time of enrolment. The primary endpoint assessed the percentage of patients who achieved at least a 1-point change from baseline on a 7-point scale, which consisted of 1) death; 2) hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4) hospitalized, requiring supplemental oxygen; 5) hospitalized, not requiring supplemental oxygen – requiring ongoing medical care (COVID-19 related or otherwise); 6) hospitalized, not requiring supplemental oxygen – no longer requires ongoing medical care; 7) discharged from hospital. A second cohort, which was partially recruited (n=27), compared Kevzara 800 mg versus placebo.

The Kevzara trial was designed after a small (n=21), single-arm study in China (Xu et al) among mostly severe, febrile hospitalized COVID-19 patients found elevated IL-6 levels and suggested that inhibiting this pathway with the IL-6 blocker tocilizumab rapidly reduced fever and improved oxygenation in severe patients, allowing for successful hospital discharge. The Phase 3 Kevzara trial was designed to evaluate this hypothesis in a large, placebo-controlled trial. The trial has been funded in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under OT number: HHSO100201700020C.

A separate Sanofi-led trial outside of the U.S. in hospitalized patients with severe and critical COVID-19 using a different dosing regimen is ongoing. The same Independent Data Monitoring Committee (IDMC) is overseeing both the Regeneron-led U.S. trial and the Sanofi-led trial outside of U.S., which has recommended that the trial outside of the U.S. continue. The companies expect to report results in Q3 2020.

1: Endpoints  that showed positive trends in patients on mechanical ventilation at baseline, and were countered by negative trends in patients who were not mechanically ventilated at baseline included: the proportion of patients with a 1-point improvement on day 22 (primary endpoint for mechanical ventilation group); the proportion of patients who died by day 29; and proportion of patients who recovered by day 22.

Latest News

FOX News

Fox News Hit With Another Workplace Lawsuit Involving Claims of Sexual Harassment, Gender Bias and Racial Discrimination

Following news in June that conservative opinion outlet Fox News had been fined a record $1 million by the New York City Commission on Human Rights for repeated worksite sexual harassment of female employees and rampant job retaliation, the cable station is now embroiled in another workplace controversy. The Associated…

Dolly Parton

Dolly Parton Used Royalties From Whitney Houston’s Cover of ‘I Will Always Love You’ To Support Nashville’s Black Community

As if her efforts to invest in COVID-19 vaccines or help to promote literacy for children weren’t enough, it appears that country music legend Dolly Parton is also a staunch supporter of efforts to help build up the Black community — especially in the home of country music, Nashville, Tennessee. …

Sheila Jackson Lee

Rep. Sheila Jackson Lee Becomes Third Black Member of Congress Arrested for Protesting Republican Anti-Voting Restrictions

Last month, we reported on Rep. Joyce Beatty, chairwoman of the Congressional Black Caucus, being arrested during a peaceful protest for voting rights reform. A few days later, Rep. Hank Johnson of Georgia was arrested in a similar protest. And now, less than two weeks after that, a third Black…

DaBaby

Rapper DaBaby Dropped From Chicago’s Lollapalooza Festival Following Series of Disturbing Homophobic and Sexist Rants

Following a hate-filled rant he made while performing at the Rolling Loud music festival in Miami, organizers of the Lollapalooza music festival in Chicago decided rapper DaBaby was no longer welcome on their stage. Ben Kesslen of NBC News has reported that “the Lollapalooza music festival canceled DaBaby’s Sunday night…

HR Professional

New Study Reveals Diversity Slate of Job Applicants Increases by 118% When Women or POC Oversee Hiring and Recruitment

If your company or organization is looking to increase the diversity of its workforce, studies suggest putting a woman or someone from an underrepresented demographic in charge of hiring. According to the Journal of Applied Psychology, when women and/or people of color head hiring committees, it can have a significant…

police officer

APA Study Reveals Police Officers Are More Condescending and Less Respectful to Black Drivers They Pull Over

For any Black man or woman who has ever been pulled over for speeding or a traffic infraction, it’s not just your imagination that police officers are more condescending, aggressive and less respectful. New research from the American Psychological Association confirms that the average police officer speaks to Black drivers…